Request a KO Cell Line Evaluation
Why This Program
Built for reliable cell line engineering
Defined Scope
300 selected targets across key research areas.
Efficient Timeline
12-week target timeline & 99% ontime delivery rate to support
research momentum.
Comprehensive QC
Detailed validation with genotype, protein-level, and STR data.
Research-Ready Delivery
Validated cell stocks and documentation for downstream use.
Target Research Areas
A comprehensive catalog of cell lines
Single-gene knockout only
One target gene and one cell line per project
{{ item.label }}
| Target | Research Area | Action |
|---|---|---|
| {{ item.target }} | {{ item.research }} |
What You Will Receive
Each qualifying project includes one validated monoclonal KO cell line and a
comprehensive identification report.
KO Cell Line
2 homozyous clones
Cell Supply
2 vials per clone, 1 × 10⁶ cells per vial
Genotype Confirmation
Sequencing-based genotype identification
Protein-Level Assessment
Protein expression verification, where technically applicable
Cell Line Authentication
STR profiling
Final Report
Comprehensive identification report
The standard goal is a homozygous monoclonal KO clone. If homozygous knockout affects cell growth or
viability, a heterozygous clone may be the technically feasible outcome.
How the Program Works
1
Submit Your Inquiry
Provide your target, preferred cell line, and project requirements.
2
Project Evaluation
Cyagen reviews eligibility and technical feasibility.
3
Contract & Initial Payment
The target timeline begins after contract signing and receipt of
initial payment.
4
Development & QC
Cyagen develops and validates the KO clone according to the agreed
scope.
5
Delivery & Report
Receive the validated cell line and identification report.
Transparent Shared-Access Terms
This discounted program is offered under a research-use shared-access model.
Research Use Rights
Clients may use the delivered cell line for internal research and
derivative studies.
Transfer Restrictions
Third-party transfer, resale, sublicensing, or distribution requires
prior written agreement.
Commercial Rights
Cyagen retains commercialization rights under this shared-access
program.
Publication Acknowledgment
For published work, clients should acknowledge Cyagen Biosciences as
the developer where appropriate.
Frequently Asked Questions (FAQs)
What if my target is not included in the 300-target
list?
Cyagen reviews eligibility and technical feasibility.
Can I request a specific cell line?
Yes. Please include your preferred cell line in the inquiry
form. Cyagen will review technical feasibility before project initiation.
Is homozygous KO guaranteed?
The standard goal is a homozygous monoclonal KO clone. If
homozygous knockout affects cell growth or viability, a heterozygous clone may be the
technically feasible outcome.
Can I use the delivered cell line with collaborators or
service providers?
The delivered cell line is intended for the client’s internal
research use. Third-party transfer, resale, sublicensing, or distribution requires prior
written agreement.
Ready to Start Your KO Cell Line Project?
Check whether your target is included and submit your project inquiry for evaluation.
This limited-time campaign is available from August 1 to December 31, 2026.
Request a KO Cell Line Feasibility Review
Cyagen will use the information below to evaluate your eligibility for the Shared-Access 300
program. Your information will be handled in accordance with Cyagen’s privacy policy.
We will review your application and contact you within 3–5 business days.
